Loading stock data…
SELLAS Life Sciences Group, Inc (SLS)
$13.96+0.10 (+0.72%)
Market ClosedLast close Sep 8
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SELLAS Life Sciences Group, Inc. in the Healthcare sector is trading at $13.96 with a market capitalization of $2.8B. Wall Street consensus targets $32.50 (2 analysts), implying a +132.8% move over the next 12 months. The stock is currently near its 52-week high of $15.88, remaining 103.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +132.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.25M↓ | -$8.26M↓ | -$7.08M↓ | -$6.87M↓ | -$6.06M |
| Net Income | -$8.41M↓ | -$7.66M↓ | -$6.79M↓ | -$6.60M↓ | -$5.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.58%
Volume
Today's trading volume
5.99M
Recent News
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data
SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...
Sellas Gears Up To Present Preclinical SLS009 Data For Pancreatic Cancer At Major Oncology Conference
Three abstracts evaluating SLS009 have been accepted for poster presentations at the AACR Conference on Pancreatic Cancer later in September.
Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here
Sellas is gaining Wall Street’s attention as clinical progress, upcoming catalysts, and positive analyst sentiment strengthen the case for further upside.
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Short seller BMF Capital disclosed a short position in SELLAS Life Sciences Group Inc., arguing the market has “dangerously overvalued” the biotech company...